TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients

Analytical Cellular Pathology

Volumn 33, Issue 1, 2010, Pages 1-11

  Faria Sarasqueta, A ^a,b   Gosens, M J E M ^b   Moerland, E ^a   Van Lijnschoten, I ^a   Lemmens, V E P P ^c   Slooter, G D ^d   Rutten, H J T ^e   Van Den Brule, A J C ^a,b,c,e  

^a Stichting Laboratoria voor Pathologie en Medische Microbiologie   (Netherlands)

^b FONTYS UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^c The Netherlands   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

Author keywords

5 FU; age; Colon carcinoma; SNP; survival; TS; VNTR

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT; AGE; COLON TUMOR; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TANDEM REPEAT;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; TANDEM REPEAT SEQUENCES; THYMIDYLATE SYNTHASE;

EID: 79952278602     PISSN: 22107177     EISSN: 22107185     Source Type: Journal    
DOI: 10.3233/ACP-CLO-2010-0526     Document Type: Article

References (53)

1. F. Amatori et al., Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients, Pharmacogenet. Genomics 16 (2006), 809-816. (Pubitemid 44632295)
2. A. Artinyan et al., Molecular predictors of lymph node metastasis in colon cancer: increased risk with decreased thymidylate synthase expression, J. Gastrointest. Surg. 9 (2005), 1216-1221. (Pubitemid 41751113)
3. O. Belvedere et al., Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer, Ann. Oncol. 15 (2004), 55-58. (Pubitemid 38139604)
4. J. Chen et al., Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer, Cancer Epidemiol. Biomarkers Prevent 12 (2003), 958-962. (Pubitemid 37310249)
5. H.-J. Cho et al., Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil associated toxicity, Therap. Drug Monitor 29(2) (2007), 190-196. (Pubitemid 46716185)
6. M. Ciaparrone et al., Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil, Oncology 70 (2006), 366-377. (Pubitemid 46066130)
7. K. Curtin et al., Thymidylate synthase polymorphisms and colon cancer: Associations with tumor stage, tumor characteristics and survival, Int. J. Cancer 120 (2007), 2226-2232. (Pubitemid 46555863)
8. D. Edler et al., Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer, Clin. Cancer Res. 6 (2000), 1378-1384. (Pubitemid 30226223)
9. M.E. Fernandez-Contreras et al., Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil, Int. J. Oncol. 28(5) (2006), 1303-1310.
10. M. Frattini et al., Different genetic features associated with colon and rectal carcinogenesis, Clin. Cancer Res. 10 (2004), 4015-4021. (Pubitemid 38812476)
11. E. Giovannetti et al., Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels, Br. J. Cancer 96 (2007), 769-775. (Pubitemid 46376640)
12. M.J. Gosens et al., Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer, Int. J. Cancer 123(8) (2008), 1941-1949.
13. E. Hitre et al., Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil, Pharmacogenet. Genomics 15 (2005), 723-730. (Pubitemid 41345324)
14. R.A. Hubner et al., Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma, Br. J. Cancer 97(10) (2007), 1449-1456. (Pubitemid 350114796)
15. B. Iacopetta et al., A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil, Br. J. Cancer 85(6) (2001), 827-830. (Pubitemid 33010548)
16. W. Ichikawa et al., Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastaric colorectal cancer, Clin. Cancer Res. 9 (2003), 786-791. (Pubitemid 36182616)
17. A. Jakobsen et al., Thymidylate synthase and methyltetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity, J. Clin. Oncol. 23(7) (2005), 1365-1369.
18. S.A. Jensen, B. Vainer and J.B. Sørensen, The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-Fluorouracil, Int. J. Cancer 120 (2006), 694-701.
19. K. Kawakami et al., Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers, Anticancer Res. 19 (1999), 3249-3252. (Pubitemid 30042617)
20. K. Kawakami et al., Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression, Clin. Cancer Res. 7 (2001), 4096-4101. (Pubitemid 34044633)
21. K. Kawakami et al., Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity, Jap. J. Cancer Res. 93 (2002), 1221-1229. (Pubitemid 36032985)
22. K. Kawakami and Y. Watanabe, Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene, Cancer Res 63 (2003), 6004-6007. (Pubitemid 37187503)
23. M. Kornmann et al., Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil, Clin. Cancer Res. 9 (2003), 4116-4124. (Pubitemid 37204028)
24. T. Lecomte et al., Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy, Clin. Cancer Res. 10 (2004), 5880-5888. (Pubitemid 39180969)
25. H.-J. Lenz et al., p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site, Clin. Cancer Res. 4 (1998), 1227-1234. (Pubitemid 28213334)
26. M. Li et al., Proteomic analysis of the aging-related proteins in human normal colon epithelial tissue, J. Biochem. Mol. Biol. 40(1) (2007), 72-81. (Pubitemid 46182738)
27. T. Liersch et al., Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy, J. Clin. Oncol. 24(25) (2006), 4062-4068. (Pubitemid 46628475)
28. D.B. Longley, D.P. Harkin and P.G. Johnston, 5-fluorouracil: mechanisms of action and clinical strategies, Nat. Rev. Cancer 3(5) (2003), 330-338. (Pubitemid 37328853)
29. G. Lurje et al., Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer, Pharmacogenet. Genomics 18(2) (2008), 161-168.
30. M.F. de Maat et al., Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles, Mol. Cancer Res. 5(5) (2007), 461-71. (Pubitemid 46903955)
31. M.V. Mandola et al., A novel single nucleotide polymorphism within 5-tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity, Cancer Res. 63 (2003), 3898-2904.
32. E. Marcuello et al., Single nucleotide polymorphism in the 5 tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients, Int. J. Cancer 112 (2004), 733-737. (Pubitemid 39435256)
33. N.J. Meropol et al., Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer, J. Clin. Oncol. 24(25) (2006), 4069-4077. (Pubitemid 46622281)
34. M. Morris, C. Platell and B. Iacopetta, A population-based study of age-related variation in clinicopathological features, molecular. Markers and outcome from colorectal cancer, Anticancer Res. 27(4C) (2007), 2833-2838. (Pubitemid 47228006)
35. H. Nakagawa et al., Age-related hypermethylation of the 5-region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development, Cancer Res. 61(19) (2001), 6991-6995.
36. E. Odin et al., Colorectal carcinomas with microsatellite instability display increased thymidylate synthase gene expression levels, Clin. Colorectal. Cancer 6(10) (2007), 720-727. (Pubitemid 350221370)
37. G.J. Peters et al., Induction of thymidylate synthase as 5-fluorouracil resistance mechanism, Biochim. Biophys. Acta 1587 (2002), 194-205. (Pubitemid 34655788)
38. S. Popat, A. Matakidoue and R.S. Houlston, Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis, J. Clin. Oncol. 22(3) (2004), 529-536. (Pubitemid 41079782)
39. S. Popat, R. Wort and R.S. Houlston, Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance, BMC Cancer 6 (2006), 150-158.
40. F. Prall et al., Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?, Oncol. Rep. 18(1) (2007), 203-209.
41. S.T. Pullarkat et al., Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy, Pharmacogenomics J. 1 (2001), 65-70. (Pubitemid 33757985)
42. A. Ruzzo et al., Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy, J. Clin. Oncol. 25(10) (2007), 1247-1254. (Pubitemid 46640571)
43. D. Salonga et al., Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase, Clin. Cancer Res. 6 (2000), 1322-1327. (Pubitemid 30226214)
44. Y. Shirota et al., ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy, J. Clin. Oncol. 19(23) (2001), 4298-4304. (Pubitemid 33096777)
45. J. Stoehlmacher et al., Amultivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer, Br. J. Cancer 91 (2004), 344-354. (Pubitemid 39037082)
46. K.W. Suh et al., Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer, J. Gastrointest. Surg. 9(3) (2005), 336-342. (Pubitemid 40327100)
47. T. Tsuji et al., Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious maker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer, Clin. Cancer Res. 9 (2003), 3700-3704. (Pubitemid 37169238)
48. K. Uchida et al., Loss of heterozygosity at the thymidyalte synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene, Clin. Cancer Res. 10 (2004), 433-439. (Pubitemid 38173979)
49. D. Vallböhmer et al., Molecular factors of 5-fluorouracil metabolism in colorectal cancer: Analysis of primary tumor and lymph node metastasis, Int. J. Oncol. 28 (2006), 527-533.
50. E. Villafranca et al., Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer, J. Clin. Oncol. 19(6) (2001), 1779-1786. (Pubitemid 32230880)
51. J.L.Westra, et al., Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients, Ann. Oncol. 16 (2005), 1646-1653.
52. Y. Xi et al., Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer, BMC Genomics 7 (2006).
53. Y. Yanagisawa et al., Modified irinotecan/5-FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes, Scan. J. Gastroenterol. 42 (2007), 477-484. (Pubitemid 46569407)